602 related articles for article (PubMed ID: 20726688)
1. Biological agents in kidney transplantation: belatacept is entering the field.
Wéclawiak H; Kamar N; Ould-Mohamed A; Cardeau-Desangles I; Rostaing L
Expert Opin Biol Ther; 2010 Oct; 10(10):1501-8. PubMed ID: 20726688
[TBL] [Abstract][Full Text] [Related]
2. Belatacept: a new biologic and its role in kidney transplantation.
Su VC; Harrison J; Rogers C; Ensom MH
Ann Pharmacother; 2012 Jan; 46(1):57-67. PubMed ID: 22215686
[TBL] [Abstract][Full Text] [Related]
3. Belatacept utilization recommendations: an expert position.
Grinyó JM; Budde K; Citterio F; Charpentier B
Expert Opin Drug Saf; 2013 Jan; 12(1):111-22. PubMed ID: 23206310
[TBL] [Abstract][Full Text] [Related]
4. Rationale for using belatacept in combination with sirolimus.
Wéclawiak H; Kamar N; Ould-Mohamed A; Cardeau-Desangles I; Rostaing L
Transplant Proc; 2010 Nov; 42(9 Suppl):S29-31. PubMed ID: 21095447
[TBL] [Abstract][Full Text] [Related]
5. Belatacept for kidney transplant recipients.
Masson P; Henderson L; Chapman JR; Craig JC; Webster AC
Cochrane Database Syst Rev; 2014 Nov; 2014(11):CD010699. PubMed ID: 25416857
[TBL] [Abstract][Full Text] [Related]
6. Belatacept : a new biological agent for maintenance immunosuppression in kidney transplantation.
Arora S; Tangirala B; Osadchuk L; Sureshkumar KK
Expert Opin Biol Ther; 2012 Jul; 12(7):965-79. PubMed ID: 22564126
[TBL] [Abstract][Full Text] [Related]
7. Belatacept-based regimens versus a cyclosporine A-based regimen in kidney transplant recipients: 2-year results from the BENEFIT and BENEFIT-EXT studies.
Larsen CP; Grinyó J; Medina-Pestana J; Vanrenterghem Y; Vincenti F; Breshahan B; Campistol JM; Florman S; Rial Mdel C; Kamar N; Block A; Di Russo G; Lin CS; Garg P; Charpentier B
Transplantation; 2010 Dec; 90(12):1528-35. PubMed ID: 21076381
[TBL] [Abstract][Full Text] [Related]
8. Belatacept in kidney transplantation.
Wojciechowski D; Vincenti F
Curr Opin Organ Transplant; 2012 Dec; 17(6):640-7. PubMed ID: 23044530
[TBL] [Abstract][Full Text] [Related]
9. Belatacept: a new era of immunosuppression?
El-Charabaty E; Geara AS; Ting C; El-Sayegh S; Azzi J
Expert Rev Clin Immunol; 2012 Aug; 8(6):527-36. PubMed ID: 22992146
[TBL] [Abstract][Full Text] [Related]
10. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
Bumbea V; Kamar N; Ribes D; Esposito L; Modesto A; Guitard J; Nasou G; Durand D; Rostaing L
Nephrol Dial Transplant; 2005 Nov; 20(11):2517-23. PubMed ID: 15985508
[TBL] [Abstract][Full Text] [Related]
11. Belatacept: a novel biologic for maintenance immunosuppression after renal transplantation.
Martin ST; Tichy EM; Gabardi S
Pharmacotherapy; 2011 Apr; 31(4):394-407. PubMed ID: 21449628
[TBL] [Abstract][Full Text] [Related]
12. T-cell phenotype in protocol renal biopsy from transplant recipients treated with belatacept-mediated co-stimulatory blockade.
Grimbert P; Audard V; Diet C; Matignon M; Plonquet A; Mansour H; Desvaux D; Durrbach A; Cohen JL; Lang P
Nephrol Dial Transplant; 2011 Mar; 26(3):1087-93. PubMed ID: 20667993
[TBL] [Abstract][Full Text] [Related]
13. Belatacept: a novel immunosuppressive agent for kidney transplant recipients.
Charpentier B
Expert Rev Clin Immunol; 2012 Nov; 8(8):719-28. PubMed ID: 23167683
[TBL] [Abstract][Full Text] [Related]
14. Costimulation targeting therapies in organ transplantation.
Gandhi AM; Fazli U; Rodina V; Qazi YA
Curr Opin Organ Transplant; 2008 Dec; 13(6):622-6. PubMed ID: 19060553
[TBL] [Abstract][Full Text] [Related]
15. Belatacept-based regimens are associated with improved cardiovascular and metabolic risk factors compared with cyclosporine in kidney transplant recipients (BENEFIT and BENEFIT-EXT studies).
Vanrenterghem Y; Bresnahan B; Campistol J; Durrbach A; Grinyó J; Neumayer HH; Lang P; Larsen CP; Mancilla-Urrea E; Pestana JM; Block A; Duan T; Glicklich A; Gujrathi S; Vincenti F
Transplantation; 2011 May; 91(9):976-83. PubMed ID: 21372756
[TBL] [Abstract][Full Text] [Related]
16. Alternatives to calcineurin inhibition in renal transplantation: belatacept, the first co-stimulation blocker.
Poirier N; Blancho G; Vanhove B
Immunotherapy; 2010 Sep; 2(5):625-36. PubMed ID: 20874646
[TBL] [Abstract][Full Text] [Related]
17. Risk of posttransplant lymphoproliferative disorder associated with use of belatacept.
Martin ST; Powell JT; Patel M; Tsapepas D
Am J Health Syst Pharm; 2013 Nov; 70(22):1977-83. PubMed ID: 24173007
[TBL] [Abstract][Full Text] [Related]
18. Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients: a randomized phase II study.
Rostaing L; Massari P; Garcia VD; Mancilla-Urrea E; Nainan G; del Carmen Rial M; Steinberg S; Vincenti F; Shi R; Di Russo G; Thomas D; Grinyó J
Clin J Am Soc Nephrol; 2011 Feb; 6(2):430-9. PubMed ID: 21051752
[TBL] [Abstract][Full Text] [Related]
19. Belatacept: in adult kidney transplant recipients.
Garnock-Jones KP
BioDrugs; 2012 Dec; 26(6):413-24. PubMed ID: 22928660
[TBL] [Abstract][Full Text] [Related]
20. Advances in immunosuppression for kidney transplantation: new strategies for preserving kidney function and reducing cardiovascular risk.
Bestard O; Campistol JM; Morales JM; Sánchez-Fructuoso A; Cabello M; Cabello V; Pallardó LM; Grinyó JM
Nefrologia; 2012 May; 32(3):374-84. PubMed ID: 22535159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
